Royal Society of Chemistry's flagship journal now free to access


The Royal Society of Chemistry (RSC) has announced that it will make its flagship journal Chemical Science free to access from the start of 2015. Chemical Science will be a gold open access journal, and operate in a similar way to other gold open access journals run by publishing houses such as the Public Library of Science or BioMed Central, charging authors a fee to have their manuscripts published – once they have been peer reviewed and accepted for publication.

Chemical Science will be free to access from January 2015, and author fees for publishing in the journal will be suspended until 2017. The outgoing UK science minister, David Willetts, applauded the move as a ‘bold step’, adding that the country was leading the way in giving publicly-funded research the widest possible audience.

Dominic Tildesley, president of the RSC, said: ‘I am delighted that my first public announcement since assuming the presidency of the Royal Society of Chemistry just last week is a momentous step forward in sharing chemical science knowledge worldwide. The Royal Society of Chemistry fully supports sustainable open access publishing, as indeed do I.’


Related Content

10 years ago: open access

21 August 2014 Flashback

news image

The start of a shift to new publishing models

Opening the doors of knowledge

1 April 2012 Feature

news image

Should all journal articles be free to access online?

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent